YS Biopharma Co., Ltd. (NASDAQ:YS) Short Interest Down 51.6% in March

YS Biopharma Co., Ltd. (NASDAQ:YS) saw a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 116,800 shares, a decrease of 51.6% from the February 29th total of 241,400 shares. Based on an average daily volume of 206,100 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.7% of the shares of the company are short sold.

Institutional Investors Weigh In On YS Biopharma

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC acquired a new stake in shares of YS Biopharma during the 1st quarter valued at $1,864,000. Superstring Capital Management LP acquired a new stake in shares of YS Biopharma during the 4th quarter valued at $166,000. Barclays PLC acquired a new stake in shares of YS Biopharma during the 2nd quarter valued at $150,000. Prelude Capital Management LLC acquired a new stake in shares of YS Biopharma during the 2nd quarter valued at $44,000. Finally, XTX Topco Ltd acquired a new stake in shares of YS Biopharma during the 2nd quarter valued at $31,000. 52.64% of the stock is currently owned by institutional investors and hedge funds.

YS Biopharma Stock Up 1.4 %

NASDAQ:YS opened at $0.72 on Friday. The stock has a 50 day moving average of $0.51 and a 200-day moving average of $0.58. YS Biopharma has a 52 week low of $0.35 and a 52 week high of $2.64. The company has a quick ratio of 1.09, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

YS Biopharma (NASDAQ:YS) last issued its quarterly earnings data on Monday, January 22nd. The company reported ($0.16) earnings per share (EPS) for the quarter. The company had revenue of $13.64 million during the quarter. Sell-side analysts expect that YS Biopharma will post -0.49 EPS for the current year.

About YS Biopharma

YS Biopharma Co, Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.